KARAM BIOSCIENCE
CellState Research
Public scope outline / 2026-10-15

Proposed research work, not an accepted engagement or demonstrated result.

DECISION
CellState Research is Karam’s proposed first proprietary development program. It would combine assay context, multiple readouts and explicit failure flags in one model and one buyer workflow. The central hypothesis is that the system can reduce false-positive development decisions and analyst time. That hypothesis has not yet been validated.

READINESS
Software in development

PLANNING BUDGET; NOT A QUOTE
$10,000–$25,000 design-partner pilot proposed

TIMING CONDITION
Delivery possible only after a usable prototype

DELIVERABLES
Narrow workflow definition: Choose one cell model, one decision and the comparison methods before expanding scope.
Context-aware analysis concept: Retain sample, batch, viability and measurement context alongside apparent molecular or image changes.
Independent benchmark plan: Hold out appropriate donors, laboratories or batches and compare with existing methods and simpler baselines.
Design-partner evaluation: Measure reproducibility, error rates and time saved against customer-defined usefulness criteria.

INPUTS
A repeated interpretation task, authorized representative datasets, baseline methods, evaluation rights and a willingness to define failure as well as success.

ACCEPTANCE
At least three independent design partners should define usefulness before a general platform is built. A paid pilot is offered only when delivery is feasible and performance tests are agreed.

BOUNDARIES
No validated diagnostic, proprietary performance claim, production software license or demonstrated advantage is currently asserted. Functional outcomes and molecular age predictions remain separate.